Piekos Brian 4

What Happened
Brian Piekos, Chief Financial Officer of KalVista Pharmaceuticals (KALV), was granted 100,000 restricted stock units (RSUs) on January 16, 2026. The award is recorded as a derivative acquisition at $0.00 per unit (i.e., contingent rights to shares rather than a cash purchase). RSUs convert to common stock upon settlement for no consideration when vested.

Key Details

• Transaction date and type: 2026-01-16 — Award/Grant (code A) of 100,000 RSUs at $0.00 each.
• Vesting: 1/16th of the total RSUs vest on each quarterly anniversary of the vesting commencement date, beginning May 22, 2026 (implies full vesting over 16 quarters / ~4 years, subject to continued service).
• Settlement: Each RSU represents a contingent right to receive one share of common stock upon settlement for no consideration (footnote F1).
• Shares owned after transaction: Not disclosed in the filing.
• Filing timeliness: Form 4 was filed on January 21, 2026 for the January 16 transaction — filed within the SEC’s two-business-day reporting window (timely).

Context
This is a standard equity compensation award to an executive, not an open-market purchase or sale. Such awards are common for retention and incentive purposes and do not by themselves signal an immediate buy or sell decision by the insider. The quarterly vesting schedule ties future share delivery to continued service.